Clinical trials: Anti-vascular Endothelial Growth Factor
Age-Related Macular Degeneration (AMD), Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD
- Trial name
- NCT02348359
- Testing
- X-82, Anti-VEGF
- Where
- 35 sites in United States
- Volunteers
- 157 people
- Sponsor
- Tyrogenex
Irvine-Gass Syndrome
Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept
This research study is being conducted to determine the safety and tolerability of subconjunctival injections of aflibercept in the treatment of pseudophakic cystoid macular edema that has not responded well to first-line…
- Trial name
- ACME (NCT03396861)
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tufts Medical Center
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Wet Macular Degeneration
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01249937)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Neovascular Age Related Macular Degeneration
NVAMD Satellite Study
Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD).
- Trial name
- NCT02251366
- Testing
- Physician-guided diagnostic
- Where
- 5 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Severe Diabetic Macular Oedema
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO).
- Trial name
- DAME (NCT06985706)
- Testing
- Subthreshold Micropulse Laser (SML), Anti-VEGF Monotherapy (standard care)
- Where
- 22 sites in United Kingdom
- Volunteers
- 264 people
- Sponsor
- Belfast Health and Social Care Trust
Diabetic Macular Edema
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
Diabetic retinopathy (DR) is considered the main etiology of blindness among working-age adults, and Diabetic macular edema (DME) is the main reason for vision loss related to DR .
- Trial name
- NCT06205979
- Testing
- Ranibizumab Injection [Lucentis], Aflibercept Injection [Eylea]
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Renal Cell Carcinoma
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
- Trial name
- NCT07049926
- Testing
- Belzutifan, Zanzalintinib
- Where
- 33 sites in United States, Chile and 6 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Wet Macular Degeneration
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to…
- Trial name
- NCT02541084
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
- Trial name
- ONYX (NCT02713204)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 87 sites in United States
- Volunteers
- 365 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular (Wet) Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Researchers are looking for a better way to treat people who have neovascular (wet) age-related macular degeneration (nAMD or wet AMD).
- Trial name
- XPAND (NCT05473715)
- Testing
- Aflibercept(BAY86-5321, Eylea)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Bayer
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study.
- Trial name
- NCT00786383
- Testing
- IMC-1121B, 1121B
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Age-Related Macular Degeneration
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent…
- Trial name
- NCT02357342
- Testing
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Age-Related Macular Degeneration
Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD
The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.
- Trial name
- NCT05678517
- Testing
- Anti-VEGF
- Where
- 2 sites in Hungary
- Volunteers
- 47 people
- Sponsor
- Semmelweis University
Diabetic Macular Edema, Macular Ischemia
Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
The Early Treatment Diabetic Retinopathy Study (ETDRS) group founded guidelines for treating patients with clinically significant diabetic macular edema (DME) with focal/grid macular laser photocoagulation.
- Conditions
- Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
- Trial name
- REBEL (NCT04991350)
- Testing
- Intravitreal ranibizumab, Intravitreal bevacizumab
- Where
- Egypt
- Volunteers
- 5 people
- Sponsor
- Cairo University
Diabetic Macular Edema (DME)
Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.
The goal of this clinical trial is to learn if the efficacy of dexamethasone implant combined with anti-VEGF superior to anti-VEGF monotherapy in the treatment of DME in Chinese patients.
- Trial name
- NCT06846073
- Testing
- The combination of intravitreal anti-VEGF and dexamethasone implants injections.
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Solid Tumors
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.
- Trial name
- NCT01004822
- Testing
- CVX-241
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Diabetic Retinopathy, Diabetic Macular Edema
Anti-VEGF Treatment for Prevention of PDR/DME
Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular…
- Trial name
- NCT02634333
- Testing
- Prompt aflibercept, Deferred laser, Deferred aflibercept
- Where
- 85 sites in United States, Canada
- Volunteers
- 399 people
- Sponsor
- Jaeb Center for Health Research
AMD
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
Purpose To report the long-term efficacy of patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) in Changhua Christian Hospital in Taiwan.
- Trial name
- OIVAEGFFAMDIT (NCT03324542)
- Testing
- Aflibercept [Eylea]
- Where
- Taiwan
- Volunteers
- 63 people
- Sponsor
- Changhua Christian Hospital